Nuvectis Pharma registers Phase 1b trial of NXP900 plus lorlatinib in ALK+ NSCLC
The trial, sponsored by Nuvectis Pharma, is recruiting at one U.S. site and aims to enroll 54 patients with advanced ALK-positive non-small cell lung cancer.
Nuvectis Pharma had one clinical trial update during the week.
- Nuvectis Pharma is the sponsor of a Phase 1b, open-label study testing NXP900, an orally administered inhibitor of SRC family kinases1, combined with lorlatinib in patients with advanced, ALK-positive non-small cell lung cancer. The record, first posted on 2026-08-25, lists the study as recruiting, with an actual start date of 2026-08-171 and planned enrollment of 54 participants (estimated)1. The study is currently listed at one site, NEXT Virginia, Fairfax, Virginia, United States (recruiting)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.